Mauna Kea Technologies Reports Second Quarter and First Half 2023 Revenue

Q2 revenue increased 77% globally, including 100% United States sales growth 

Pipeline of new potential strategic partnerships continues to build 

 

Paris and Boston, July 20, 2023 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its revenue for the second quarter and half year ended June 30, 2023. 

Highlights:

• Revenue up 77% in Q2 2023 driven by U.S. sales growth and licensing fee income from the J.V. with Tasly Pharmaceutical 
• PPU growth accelerates to 50%, benefitting from increased utilization and new users
• Clinical development activity remains high, including a new dual-center peripheral lung cancer study at the Mayo Clinic in Jacksonville and Rochester in the United States 
• Growing strategic partnership pipeline reflects increasing role of Cellvizio interventional oncology advanced imaging in new procedures 

Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “Building on strong Q1 results, we are very pleased with our Q2 commercial performance, led by notable U.S. sales momentum in systems and consumables, as well as our PPU (pay-per-use) program, despite ongoing fluorescein supply issues. Strategically, the Mauna Kea team has done an excellent job advancing the implementation of our previously announced Joint Venture with Tasly Pharmaceutical, a collaboration that is core to capturing the large and growing Chinese domestic market. Finally, we are exploring an expanding number of strategic partnership opportunities, where we see the potential to accelerate the adoption of Cellvizio in novel indications, a strategy we believe creates capital efficient growth potential and value for our shareholders.”